Retatrutide
GLP-1/GIP/Glucagon agonist
The investigational triple agonist combining appetite control with an energy-expenditure signal.
Research chemical vendors can't legally label products with the real name, so Retatrutide often appears under coded SKUs. If you're shopping and see any of these, it's the same compound:
- 3R· Common shorthand
- Branch-3R· Branch Peptides
- Ion-3R· Ion Peptides
- GLP-3
- GLP3
- Triple-R
- Reta
- LY-3437943
Codes shown are for identification only. Always verify third-party COAs before purchase.
Retatrutide is a once-weekly investigational medicine that activates GLP-1, GIP, and glucagon receptors. GLP-1 and GIP affect appetite, insulin response, and blood glucose; the glucagon component may also increase energy expenditure. In a 48-week Phase 2 obesity trial, the highest-dose group had a mean weight reduction of about 24%, but that result cannot be compared directly with a different trial or treated as a guarantee. Retatrutide is not currently an approved prescription medicine, and its long-term benefit-risk profile is still being studied.
Retatrutide remains investigational. Published trials used gradual dose escalation to improve tolerability. Nausea, vomiting, diarrhea, constipation, and increased heart rate have been reported. It should not be described as an approved alternative to semaglutide or tirzepatide.
- Interest in the strongest average weight-loss signal reported among late-stage incretin studies
- Research into obesity, insulin resistance, and reduction of excess liver fat
- Once-weekly action across three metabolic receptor pathways
- Important distinction: trial results come from controlled investigational use, not unverified research products
Educational only · Not a vendor claim
Activates GLP-1, GIP, and glucagon receptors in one investigational molecule. The first two pathways influence satiety and glucose regulation, while glucagon receptor activity may raise energy expenditure and fat oxidation.
- Mean weight reduction approached 24% at 48 weeks in the highest-dose Phase 2 group
- Promising reductions in waist circumference and cardiometabolic risk markers
- Research signal for reducing excess liver fat
- Once-weekly pharmacology
- Appetite and food intake may fall substantially
- Weight change builds over months rather than days
- GI tolerance can change after each escalation
- Resting heart rate may increase
- Three complementary metabolic targets
- Leading investigational weight-loss efficacy signal
- Being studied in large late-stage clinical programs
- Potential beyond appetite reduction alone
- Not approved for routine clinical use
- No mature long-term safety record
- Trial percentages are not directly comparable across different studies
- Unverified products do not replicate clinical-trial quality controls
- Nausea or vomiting
- Diarrhea or constipation
- Reduced appetite and fatigue
- Increased heart rate
- Potential class risks involving gallbladder, pancreas, dehydration, and severe GI symptoms
Educational summary · Not medical advice · Discuss with a qualified clinician
Typical timeline
General pattern for the Fat Loss category. Individual response varies.
- Week 1Titrate up slowly. Expect appetite drop, mild nausea, and possible constipation with GLP-1s. Hydrate and lean on fiber.
- Weeks 2–4Steady weight trend down (0.5–1.5 lb/week is healthy). Prioritize protein (~1 g/lb lean mass) to protect muscle.
- Weeks 4–8Body composition visibly shifts. Add resistance training if you haven't — muscle preservation is the whole game.
- Weeks 8+Re-evaluate dose. Consider a maintenance drop or a scheduled break to reset receptor sensitivity.
Pairs well with
Common combinations experienced users run alongside Retatrutide. Always add one peptide at a time so you can attribute effects and side effects.
Read the safety guide before stacking.
The reconstitution math
- 1Reconstitute the 10 mg vial with 2 mL of bacteriostatic water. Tilt — don't shake.
- 2Concentration becomes 5,000 mcg/mL (5 mg/mL).
- 3For a 2 mg dose, draw 0.400 mL — that's 40 units on a 1 mL insulin syringe.
- 4One vial gives you approximately 5 doses.
Reminder: 100 units on an insulin syringe = 1 mL. Always start at half the listed dose for the first week and rotate injection sites between arms, legs, abdomen, and glutes.
Sign in to keep a private log of your doses and notes for Retatrutide.
Use code ANYPEPTIDES15 for 15% off your order.
Discount may end or change without notice.